RxDoctor Payments Data

Anna Goodge, NP

Family · Santa Maria, CANPI 1972844157

Payments from drug & device makers

$1,192in general payments, 2019–2025

Across 36 payments — averaging $33.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$276
  • Amgen$194
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$164
  • GSK$123
  • Atricure, Inc.$107
  • AstraZeneca$87
  • plus $240 from 6 others

What the payments were for

  • Food & beverage$1,08391%
  • Education$1099%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,192 in reported general payments places this provider in the 75th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$177,803
Medicare patients
949
Services billed
2,704

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban414$380,122
EntrestoSacubitril/Valsartan128$139,692
XareltoRivaroxaban100$92,901
Repatha SureclickEvolocumab52$36,970
JardianceEmpagliflozin33$34,114
Praluent PenAlirocumab54$30,099
BrilintaTicagrelor18$21,651
VerquvoVericiguat15$15,458
Repatha PushtronexEvolocumab14$8,025
Ezetimibe106$5,177
Metoprolol Succinate297$3,910
Rosuvastatin Calcium161$3,193
Atorvastatin Calcium296$2,136
Warfarin Sodium143$1,941
Carvedilol188$1,337

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$54$139,692128 claims
Boehringer IngelheimJardiance$21$34,11433 claims
AstraZenecaBrilinta$87$21,65118 claims
MerckVerquvo$22$15,45815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,634 family providers in California.

Other family in Santa Maria

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →